Relief Therapeutics Holding AG (RLFTF)

[TurdBlossom]

The Aviptadil inhalation trial is huge news especially since the age group to be studied is 12-85 yrs old. Currently those under the age of 21 are not a priority for vaccination because they account for 0.08% of Covid19 related deaths in the US, yet those under 21 account for about 26% of the US population.
Children can get sick from the Covid19 virus and children can suffer longer term effects, like multi system inflammatory disease of children (MISC). Should additional studies demonstrate that a VIP inhaler administered at home is safe and effective for the pediatric population, we are looking at the key to returning to a normal life at the very least and very possibly a novel SOC for how viral respiratory infections are treated. Exciting times! IMO